Cargando…

High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy

Recent advances in single-cell transcriptomics have greatly improved knowledge of complex transcriptional programs, rapidly expanding our knowledge of cellular phenotypes and functions within the tumour microenvironment and immune system. Several new single-cell technologies have been developed over...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quek, Camelia, Bai, Xinyu, Long, Georgina V., Scolyer, Richard A., Wilmott, James S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535767/ https://www.ncbi.nlm.nih.gov/pubmed/34681023 http://dx.doi.org/10.3390/genes12101629

Ejemplares similares

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
por: Lee, Hansol, et al.
Publicado: (2021)

Unravelling Tumour Microenvironment in Melanoma at Single-Cell Level and Challenges to Checkpoint Immunotherapy
por: Bai, Xinyu, et al.
Publicado: (2022)

Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma
por: Yaseen, Zarwa, et al.
Publicado: (2022)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
por: Conway, Jordan W., et al.
Publicado: (2022)

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas
por: Quek, Camelia, et al.
Publicado: (2019)

Causes, consequences and clinical significance of aneuploidy across melanoma subtypes
por: Shteinman, Eva R., et al.
Publicado: (2022)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
por: Mao, Yizhe, et al.
Publicado: (2023)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors
por: Ziemys, Arturas, et al.
Publicado: (2020)

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis
por: Krisp, Christoph, et al.
Publicado: (2018)

Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis
por: Nahar, Kazi J., et al.
Publicado: (2022)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
por: Lim, Su Yin, et al.
Publicado: (2017)

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
por: Shklovskaya, Elena, et al.
Publicado: (2020)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma
por: Haas, Lisa, et al.
Publicado: (2021)

Expression of NGF/proNGF and Their Receptors TrkA, p75(NTR) and Sortilin in Melanoma
por: Marsland, Mark, et al.
Publicado: (2022)

Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome
por: Attrill, Grace H., et al.
Publicado: (2022)

Genetics and Genomics of Melanoma: Current Progress and Future Directions
por: Quek, Camelia
Publicado: (2023)

Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation
por: Wang, Minyu, et al.
Publicado: (2022)

Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value
por: Barnhill, Raymond, et al.
Publicado: (2020)

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
por: Menzies, A M, et al.
Publicado: (2014)

Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis
por: Wu, Sunny Z., et al.
Publicado: (2021)

Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications
por: Kiyohara, Eiji, et al.
Publicado: (2015)

Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling
por: Chien, Andy J., et al.
Publicado: (2014)

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
por: Lee, Jenny H., et al.
Publicado: (2020)

TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells
por: Sutton, Selina K., et al.
Publicado: (2014)

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
por: Conway, Jordan W, et al.
Publicado: (2022)

Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition
por: Park, John J., et al.
Publicado: (2021)

Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
por: Livingstone, Ann, et al.
Publicado: (2021)

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
por: Pennington, Thomas E, et al.
Publicado: (2022)

A pretreatment transcriptomic signature that predicts outcomes of immunotherapy in melanoma
por: Hu, Junjie, et al.
Publicado: (2022)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

The current landscape of single-cell transcriptomics for cancer immunotherapy
por: Guruprasad, Puneeth, et al.
Publicado: (2020)

Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells
por: Liu, Yi Lun, et al.
Publicado: (2014)

High-dimensional immune-profiling in cancer: implications for immunotherapy
por: Chuah, Samuel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fe9mdj8gg7j81a942sfaghafi8